EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY 4.0

Early initiation of inhaled corticosteroid–long‐acting β 2 ‐agonist therapy and reduction of severe asthma exacerbations in high‐risk preschool children: A longitudinal real‐world cohort study

Arthur H Owora iD, Bowen Jiang, Yash Shah

Pediatric Allergy and Immunology · 2026

DOI: 10.1111/pai.70411 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Pediatric Allergy and Immunology, 2026. Verfasst von Arthur H Owora und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pediatric Pulmonology, Allergy/Immunology and Sleep Medicine, Department of Pediatrics, Indiana University School of Medicine, Indianapol…. Hauptthemen laut MEDLINE: Asthma, Adrenal Cortex Hormones, Adrenergic beta-2 Receptor Agonists, Anti-Asthmatic Agents. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Evidence supporting inhaled corticosteroid plus long‐acting β 2 ‐agonist (ICS + LABA) therapy in preschool children with asthma remains limited, and guideline recommendations remain cautious. However, real‐world effectiveness in high‐risk young children has not been adequately characterized.

Objective

To evaluate short‐ and long‐term effectiveness of ICS + LABA initiation on severe asthma exacerbations (SAEs) and determine whether early‐life asthma risk burden modifies treatment response.

Methods

We conducted a retrospective longitudinal cohort study using electronic health record data from the Indiana Network for Patient Care (2010–2024). Children aged ≤11 years with asthma who initiated ICS + LABA between 2010 and 2023 and had ≥12 months of pre‐ and post‐initiation follow‐up were included. The primary outcome was ≥1 SAE per year, defined per ATS/ERS criteria as asthma‐related hospitalization or emergency department admission. Piecewise generalized linear mixed‐effects models estimated annualized changes in SAE odds before versus after ICS + LABA initiation. Recurrent events were analyzed using Andersen–Gill models. Effect modification by age at diagnosis, age at prior ICS initiation, and early‐life asthma risk burden (passive digital marker [PDM] score) was assessed.

Results

Among 249 children (mean age at asthma diagnosis 2 years; at ICS + LABA initiation 5 years), annualized SAE incidence increased before initiation and declined thereafter. Adjusted SAE odds decreased by 15% per year following ICS + LABA initiation (aOR 0.85; 95% CI 0.58–0.98). Recurrent‐event modeling demonstrated a 68% reduction in SAE hazard after ICS + LABA initiation (aHR 0.32; 95% CI 0.26–0.38), exceeding reductions observed with ICS alone (aHR 0.49). Treatment benefit was greatest among children initiating ICS before age 5 years (aOR 0.77; 95% CI 0.65–0.92) and those with high early‐life asthma risk burden (aOR 0.80; 95% CI 0.67‐0.97). No significant heterogeneity was observed by sex, race, or formulation.

Conclusions

ICS + LABA initiation was associated with sustained reductions in severe exacerbations, including among preschool children, in real‐world clinical practice. These findings suggest that strict age‐based treatment restrictions may not fully capture heterogeneity in exacerbation risk and support further prospective evaluation of risk‐stratified escalation strategies. image

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AsthmaAdrenal Cortex HormonesAdrenergic beta-2 Receptor AgonistsAnti-Asthmatic AgentsHumansFemaleMaleChild, PreschoolLongitudinal StudiesRetrospective StudiesAdministration, InhalationChildDisease ProgressionTreatment OutcomeSeverity of Illness IndexHospitalizationDrug Therapy, Combination

Stichwörter der Autor:innen

inhaled corticosteroidslong‐acting β2‐agonistspediatric asthma phenotypespreschool asthmarisk stratificationsevere asthma exacerbations

Substanzen

Adrenal Cortex HormonesAdrenergic beta-2 Receptor AgonistsAnti-Asthmatic Agents

Autor:innen und Institutionen

  • Division of Pediatric Pulmonology, Allergy/Immunology and Sleep Medicine, Department of Pediatrics, Indiana University School of Medicine, Indianapolis, Indiana, USA.
  • Center for Biomedical Informatics, Regenstrief Institute, Indianapolis, Indiana, USA.

ORCID-Profile: Arthur H Owora

Förderung

  • NIH HHS
  • National Institutes of Health

Zitieren

APA

Owora, A. H., Jiang, B., & Shah, Y. (2026). Early initiation of inhaled corticosteroid–long‐acting β 2 ‐agonist therapy and reduction of severe asthma exacerbations in high‐risk preschool children: A longitudinal real‐world cohort study. Pediatric Allergy and Immunology. https://doi.org/10.1111/pai.70411

Vancouver

Owora AH, Jiang B, Shah Y. Early initiation of inhaled corticosteroid–long‐acting β 2 ‐agonist therapy and reduction of severe asthma exacerbations in high‐risk preschool children: A longitudinal real‐world cohort study. Pediatric Allergy and Immunology. 2026. doi:10.1111/pai.70411

BibTeX
@article{Owora2026,
  author = {Owora, Arthur H and Jiang, Bowen and Shah, Yash},
  title = {Early initiation of inhaled corticosteroid–long‐acting β 2 ‐agonist therapy and reduction of severe asthma exacerbations in high‐risk preschool children: A longitudinal real‐world cohort study},
  journal = {Pediatric Allergy and Immunology},
  year = {2026},
  doi = {10.1111/pai.70411}
}
Kostenlos starten →